Safe

Safe Capital Expenditures

The Capital Expenditures (CapEx) of Safe (ALSAF.PA) as of Nov 5, 2026 is -140,000.00 EUR. In the previous year, Capital Expenditures (CapEx) was -5,000.00 EUR — a change of 2,700.00% (lower).

Capital Expenditures

-140,000.00EUR

YoY

2,700.00%

Last updated:

Capital Expenditures (CapEx) of Safe is 2025 -140,000.00 EUR. Capital Expenditures (CapEx) of Safe was 2024 -5,000.00 EUR. It decreases by 2,700.00% lower compared to the previous year.

The Safe Capital Expenditures history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Capital Expenditures
Date
Capital Expenditures
Jan 1, 2018
-124.00 EUR
Jan 1, 2019
-451,000.00 EUR
Jan 1, 2020
-548,000.00 EUR
Jan 1, 2021
-1.96 M EUR
Jan 1, 2022
-858,000.00 EUR
Jan 1, 2023
-56,000.00 EUR
Jan 1, 2024
-5,000.00 EUR
Jan 1, 2025
-140,000.00 EUR
The Safe Capital Expenditures history
YEARCapital ExpendituresYoY
-140,000.00EUR+2,700.00%
-5,000.00EUR-91.07%
-56,000.00EUR-93.47%
-858,000.00EUR-56.16%
-1.96 MEUR+257.12%
-548,000.00EUR+21.51%
-451,000.00EUR+363,609.68%
-124.00EUR+40.91%
-88.00EUR-38.46%
-143.00EUR-72.61%
-522.00EUR-33.59%
-786.00EUR—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Safe Stock analysis

What does Safe do? Safe SA generates revenue through the development, production, and commercialization of spinal surgery products. The company offers SteriSpine PS, a Pedicle Screw System, and SteriSpine LC, a Lumbar Cage System, both designed for safe implant positioning and surgical access. These products feature quick change handles, dual trials, and impact removal mechanisms, utilizing polyarylamid material reinforced with 50% glass fibers. The primary buyers are healthcare providers and hospitals specializing in orthopaedic surgery, focusing on minimally invasive spinal procedures. The firm's product portfolio targets spinal surgery segments requiring precise implant placement and efficient surgical workflows. SteriSpine PS and SteriSpine LC are marketed to medical professionals seeking reliable solutions for spinal stabilization. The company's focus on polyarylamid-based materials ensures durability and compatibility with surgical requirements. Sales are driven by the demand for advanced spinal surgery tools that enhance procedural safety and reduce operation times. Safe SA's commercial strategy emphasizes direct sales to orthopaedic departments and surgical centers. The company's products are positioned as premium solutions within the spinal surgery market, catering to institutions prioritizing patient safety and surgical precision. By concentrating on a limited range of high-demand products, Safe SA maintains a focused approach to market penetration and customer satisfaction. Safe is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Safe stock

Capital Expenditures (CapEx) of Safe is -140,000.00 EUR in 2025.

Capital Expenditures (CapEx) of Safe changed from -5,000.00 EUR to -140,000.00 EUR, representing a 2,700.00% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Capital Expenditures (CapEx) Safe since 2006 – with annual values, charts, and detailed analysis.

Capital expenditures represent investments in long-term assets such as property, equipment, and technology. CapEx is essential for maintaining and growing the business.

Capital Expenditures (CapEx)'s EUR is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Capital Expenditures (CapEx)'s Safe historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — Safe

All Key Metrics — Safe